This study was conceived and designed by Dr. Krueger. He then obtained support for his project from Biogen, Inc. Dr. Krueger designed the protocol, generated the primary end-points and the secondary endpoints, and determined the required laboratory parameters to be followed. The study drug interferes with T-cell activation. The study drug was a soluble ligand for CD2 (a T-cell co-stimulation signal) designed to block T-cell activation. The soluble ligand is a cloned portion of the LFA-3 protein (the CD2 ligand) extracellular domain, which was engineered to be fused with CH2 and CH3 segments of human IgG1 as a means of increasing plasma half-life. The drug was found to be well tolerated, and there was clear clinical evidence of efficacy. The results of this study are now in preparation for publication.
Showing the most recent 10 out of 535 publications